Anatomical-Clinical Base of Adenocarcinoma Pancreatic
BACAP-2
2 other identifiers
observational
1,500
1 country
8
Brief Summary
BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2023
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2023
CompletedFirst Posted
Study publicly available on registry
November 13, 2023
CompletedStudy Start
First participant enrolled
November 16, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2035
March 19, 2026
March 1, 2026
11.2 years
November 7, 2023
March 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Enrichment of prospective BACAP collection
This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound
5 years
Interventions
Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
Eligibility Criteria
Patients with a pancreatic adenocarcinoma proven cytologically or histologically without any treatment
You may qualify if:
- Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
- Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
- Patient with pancreatic adenocarcinoma proven histologically and/or cytologically
You may not qualify if:
- Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
- Pregnant or breastfeeding patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
Béthune hospital center
Béthune, 62408, France
Haut-Lévêque Hospital
Bordeaux, 33604, France
Huriez Hospital
Lille, 59037, France
Jean Mermoz private hosptila
Lyon, 69008, France
Saint Eloi Hospital
Montpellier, 34295, France
Regional Cancer Center From Montpellier
Montpellier, 34298, France
PAU hospital
Pau, 6400, France
Rangueil hospital
Toulouse, 31059, France
Related Publications (1)
Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8.
PMID: 38853244DERIVED
Biospecimen
blood sample and micro-biopsy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Barbara BOURNET, MD, PhD
University Hospital, Toulouse
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2023
First Posted
November 13, 2023
Study Start
November 16, 2023
Primary Completion (Estimated)
January 31, 2035
Study Completion (Estimated)
February 28, 2035
Last Updated
March 19, 2026
Record last verified: 2026-03